Interview: Éric Gervais, Executive Vice President, Médunik Canada
As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate…
Médunik Canada is dedicated to developing strong partnerships with non-Canadian pharmaceutical and biopharmaceutical companies that are attempting to optimize the return on investment of their orphan drugs; they need to balance the financial risks and complexities associated to the introduction and distribution of their products on the small-size Canadian market. Through in-licensing partnerships, Médunik Canada offers turn-key operations – ranging from regulatory approval strategy to post-approval activities – to assure the commercial success of the partners’ product development efforts.
Medunik Canada
950, boul. Michèle-Bohec
Blainville (Québec) Canada
J7C 5E2
Tel.: + 1 450 433-4441
Fax: + 1 450 433-2211
As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate…
Tony Cruz of Transition Therapeutics discusses the challenges of biotech companies in Canada and his company’s unique business model that has adapted to the changing needs of big pharma through…
Tom Reeves of Interface Biologics (IBI) offers his input about the company’s roadmap towards commercialization, as well as IBI’s differentiation and the advantages of collaborating with international partners. You joined…
Sue Paish, Lifelabs’ Chief Executive Officer discusses the company’s recent purchase of BC Biomedical, why the market in BC and Ontario are so attractive, and the motivation behind LifeLabs’ collaboration…
Michael Cloutier, President of InterMune, elaborates on the challenges of navigating the Canadian healthcare system as a small pharmaceutical company, and highlights some methods by which Canada can provide a…
Investissement Québec is a public corporation whose mission is to contribute to Québec’s economic development. Investissement Québec’s project manager, Stéphanie Murphy, discusses the role and contribution of pharmaceutical companies to…
MEDEC is the national association created by and for the Canadian medical technology industry. Brian Lewis, MEDEC’s CEO explains the challanges in advocating for a responsive, safe and sustainable healthcare system…
Charles River is the fifth largest CRO globally and the Canadian affiliate is the largest preclinical organization worldwide. Glenn Washer talks to us about the environment for contract research in…
Rémi Quirion, Chief Scientist of Québec, discusses how Canada needs to promote itself more aggressively, and highlights ways in which Canada can use industry-academia partnerships to its advantage, as well…
Wayne Samuels, partner at PwC Canada, discusses the most pressing issues in the country’s healthcare system and pharmaceutical industry, and outlines the changing dynamics in Canada’s pharma business model. What…
Michael Seckler of Ferring Canada offers his input about the affiliate’s recent restructuring, as well as the challenges of Canada’s reimbursement and pricing schemes and the advantages of the company’s…
Kevin Leshuk, Vice-President and General Manager of Celgene in Canada, offers his critique of the Canadian reimbursement and approval process as well as the advantages his affiliate enjoys in specialty…
Hervé Lilliu, General Manager of UCB Canada, describes Canada’s need to support the global pharma-ceutical industry rather than vice versa, and highlights examples of ways in which Canada’s slumbering R&D…
See our Cookie Privacy Policy Here
